Vanguard Personalized Indexing Management LLC Raises Stock Position in Sutro Biopharma, Inc. $STRO

Vanguard Personalized Indexing Management LLC increased its holdings in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 174.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,617 shares of the company’s stock after purchasing an additional 38,561 shares during the period. Vanguard Personalized Indexing Management LLC owned approximately 0.07% of Sutro Biopharma worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in STRO. Vontobel Holding Ltd. raised its stake in Sutro Biopharma by 100.0% in the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company’s stock valued at $33,000 after purchasing an additional 25,000 shares during the last quarter. Vestal Point Capital LP raised its stake in Sutro Biopharma by 1.2% in the 1st quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company’s stock valued at $1,692,000 after purchasing an additional 30,000 shares during the last quarter. Cerity Partners LLC acquired a new position in Sutro Biopharma during the first quarter worth about $25,000. Invesco Ltd. boosted its position in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after acquiring an additional 53,390 shares during the last quarter. Finally, State of Wyoming acquired a new position in Sutro Biopharma during the first quarter worth about $62,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Up 10.5%

Shares of NASDAQ:STRO opened at $1.16 on Tuesday. Sutro Biopharma, Inc. has a 52 week low of $0.52 and a 52 week high of $4.60. The company’s 50 day moving average is $0.92 and its two-hundred day moving average is $0.86. The company has a market cap of $98.33 million, a PE ratio of -0.46 and a beta of 1.61.

Sutro Biopharma (NASDAQ:STRO) last posted its earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.25. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. As a group, equities research analysts expect that Sutro Biopharma, Inc. will post -2.92 EPS for the current year.

Insider Activity

In other Sutro Biopharma news, Director Connie Matsui bought 50,000 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was purchased at an average cost of $0.80 per share, for a total transaction of $40,000.00. Following the acquisition, the director owned 50,000 shares of the company’s stock, valued at $40,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 111,754 shares of company stock valued at $89,601. Company insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on STRO. Weiss Ratings restated a “sell (e+)” rating on shares of Sutro Biopharma in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Sutro Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Finally, Wells Fargo & Company lowered their price target on shares of Sutro Biopharma from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 12th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $4.47.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.